Next Article in Journal
mTOR Pathways in Cancer and Autophagy
Next Article in Special Issue
Contemporary Management of Localized Resectable Pancreatic Cancer
Previous Article in Journal
EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs
Previous Article in Special Issue
Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics
Review

Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy

1
Division of Cancer Sciences, University of Manchester, Manchester M13 9NT, UK
2
Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(1), 17; https://doi.org/10.3390/cancers10010017
Received: 14 December 2017 / Revised: 8 January 2018 / Accepted: 10 January 2018 / Published: 12 January 2018
(This article belongs to the Special Issue Latest Development in Pancreatic Cancer)
Pancreatic ductal adenocarcinoma (PDAC) continues to be a disease with poor outcomes and short-lived treatment responses. New information is emerging from genome sequencing identifying potential subgroups based on somatic and germline mutations. A variety of different mutations and mutational signatures have been identified; the driver mutation in around 93% of PDAC is KRAS, with other recorded alterations being SMAD4 and CDKN2A. Mutations in the deoxyribonucleic acid (DNA) damage repair pathway have also been investigated in PDAC and multiple clinical trials are ongoing with DNA-damaging agents. Rare mutations in BRAF and microsatellite instability (MSI) have been reported in about 1–3% of patients with PDAC, and agents used in other cancers to target these have also shown some promise. Immunotherapy is a developing field, but has failed to demonstrate benefits in PDAC to date. While many trials have failed to improve outcomes in this deadly disease, there is optimism that by developing a better understanding of the translational aspects of this cancer, future informed therapeutic strategies may prove more successful. View Full-Text
Keywords: pancreatic adenocarcinoma; mutations; molecular profiling; clinical implications pancreatic adenocarcinoma; mutations; molecular profiling; clinical implications
Show Figures

Figure 1

MDPI and ACS Style

Pihlak, R.; Weaver, J.M.J.; Valle, J.W.; McNamara, M.G. Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers 2018, 10, 17. https://doi.org/10.3390/cancers10010017

AMA Style

Pihlak R, Weaver JMJ, Valle JW, McNamara MG. Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers. 2018; 10(1):17. https://doi.org/10.3390/cancers10010017

Chicago/Turabian Style

Pihlak, Rille, Jamie M.J. Weaver, Juan W. Valle, and Mairéad G. McNamara 2018. "Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy" Cancers 10, no. 1: 17. https://doi.org/10.3390/cancers10010017

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop